REVISTA DESTACADA

Modulación farmacológica vía CCL2 / CCR2 del dolor neuropático

Valoración Valoración: 5 Estrellas

Descripción: El inhibidor de la microglia minociclina y el antagonista CCR2 (RS504393) atenúan los síntomas de dolor neuropático en ratas

TITULO FUENTE ORIGINAL:

Direct and indirect pharmacological modulation of CCL2/CCR2 pathway results in attenuation of neuropathic pain — In vivo and in vitro evidence

AUTORES:

Piotrowskaa A., Kwiatkowskia K., Rojewskaa E., Slusarczykb J., Makucha W., Basta-Kaimb A., Przewlockaa B., Mikaa J.

REVISTA ABREV.:

J Neuroimmunol

AÑO:

2016

REFERENCIA:

297:9-19

DOI:

10.1016/j.jneuroim.2016.04.017

RESUMEN ORIGINAL:

The repeated administration of microglial inhibitor (minocycline) and CCR2 antagonist (RS504393) attenuated the neuropathic pain symptoms in rats following chronic constriction injury of the sciatic nerve, which was associated with decreased spinal microglia activation and the protein level of CCL2 and CCR2. Furthermore, in microglia primary cell cultures minocycline downregulated both CCL2... + Leer más

The repeated administration of microglial inhibitor (minocycline) and CCR2 antagonist (RS504393) attenuated the neuropathic pain symptoms in rats following chronic constriction injury of the sciatic nerve, which was associated with decreased spinal microglia activation and the protein level of CCL2 and CCR2. Furthermore, in microglia primary cell cultures minocycline downregulated both CCL2 and CCR2 protein levels after lipopolysaccharide-stimulation. Additionally, in astroglia primary cell cultures minocycline decreased the expression of CCL2, but not CCR2. Our results provide new evidence that modulation of CCL2/CCR2 pathway by microglial inhibitor as well as CCR2 antagonist is effective for neuropathic pain development in rats.

- Leer menos